Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
February 6, 2026
What were the key takeaways from Philip Morris International Inc.'s February 6, 2026 earnings call?
In the fourth quarter of 2025, Philip Morris International Inc. (PM:US) reported strong financial results, with total net revenues exceeding $40 billion for the year and adjusted diluted EPS of $7.54, marking a 15% growth. The company experienced a notable 12.8% increase in smoke-free product volumes, driven primarily by IQOS and ZYN, despite facing supply constraints and competitive pressures. For 2026, management has set an organic net revenue growth guidance of 5% to 7% and adjusted diluted EPS growth of 7.5% to 9.5%, reflecting confidence in continued smoke-free momentum and robust cash generation.
What topics did Philip Morris International Inc. cover?
- Smoke-Free Product Growth: PMI achieved a remarkable 12.8% growth in smoke-free product volumes, contributing nearly $17 billion to total revenues. CEO Jacek Olczak stated, "Our leading global position in smoke-free products enables us to deliver a fifth consecutive year of positive volumes with rapid topline progress."
- Earnings Performance: Adjusted diluted EPS reached $7.54, exceeding expectations and reflecting a 15% year-over-year growth. CFO Emmanuel Babeau noted, "Excellent currency-neutral adjusted diluted EPS growth of plus 14.2% was ahead of our expectation."
- Guidance for 2026: Management provided guidance for 2026, expecting organic net revenue growth of 5% to 7% and adjusted diluted EPS growth of 7.5% to 9.5%. This guidance reflects confidence in the smoke-free business despite anticipated headwinds from excise tax increases in Japan.
- Market Expansion and Innovation: PMI's smoke-free products are now available in 106 markets, with significant growth in new regions like Taiwan. Olczak emphasized, "We have a substantial opportunity in the U.S., where ZYN grew shipments by 37% despite supply constraints in the first half."
- Combustible Products Performance: Combustible products showed resilience with low single-digit growth, driven by strong pricing strategies. Babeau stated, "Combustible performed well in 2025 with low single-digit top line growth and low to mid-single-digit gross profit growth."
What were Philip Morris International Inc.'s February 6, 2026 results?
- Total Revenue: $40B (vs $39B est, +6% YoY)
- Adjusted EPS: $7.54 (beat by $0.12)
- Smoke-Free Volume Growth: 12.8% (vs 10% est)
- Organic Net Revenue Growth Guidance: 5% to 7% (vs previous guidance of 6% to 8%)
- Adjusted Operating Margin: 40.4% (up from 39% YoY)
- Operating Cash Flow: $12.2B (matching record delivery of 2024)
Overall, PMI's strong performance in 2025 and positive outlook for 2026 reinforce the investment thesis centered around the company's successful transition to smoke-free products. Key catalysts include the continued growth of ZYN and IQOS, while risks such as regulatory challenges and competitive pressures in the U.S. warrant close monitoring.
Earnings Call Speaker Segments
James Bushnell
executiveHello, and thanks for being here. We put out a press release earlier today with the full details of our results for the fourth quarter and the entire year of 2025. You can find that release on our site, pmi.com. A glossary of terms — which covers how we define smoke-free products, along with adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures mentioned in this presentation — appears in the company's Form 8-K bearing today's date, and also on our IR websites. Remarks today include forward-looking statements and projections of future results. Please look at the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that might cause actual results to differ materially from projections or forward-looking statements. With me today are Jacek Olczak, Group CEO of PMI, and Emmanuel Babeau, Chief Financial Officer. Jacek, over to you.
Jacek Olczak
executiveThanks, James, and hello to everyone joining. For PMI, 2025 turned out to be yet another remarkable year. Adult smokers moving toward reduced-risk options represents a durable, structural shift — one we keep spearheading and that keeps producing robust, ongoing expansion for us. Because we hold the top global spot in smoke-free offerings, we managed a fifth straight year of volume gains, paired with swift revenue growth and considerable margin improvement. Shipment volumes for our smoke-free lineup climbed a superb 12.8%, and the portfolio's rising profitability showed up as organic smoke-free gross profit expansion of 18.7%. IQOS stays the primary engine, since shipments and adjusted IMS each rose roughly 11%; that figure captures a striking pickup during Q4, marked by a comeback to solid double-digit gains in Italy plus a highly encouraging launch in Taiwan — merely two illustrations of widespread geographic momentum. These results likewise demonstrate how well our multi-category approach is working, as BONDS, ZYN ex-Nordics, and VEEV each more than doubled shipment volumes across international markets. Having a powerful brand lineup — spanning premium, science-backed offerings across all three smoke-free categories — lets us serve consumers better while lifting our financial results. Even though the nicotine pouch segment is still young across most markets, ZYN picked up considerable international share as we broadened both the product range and our geographic footprint. Within the more mature e-vapor space, VEEV stands as the fastest-growing brand among any major competitor in international closed pods, ranks first in eight markets, and posted a sizable gross profit gain. Our results keep being propelled by the international business, which drove the overwhelming share of total PMI organic net revenue growth, led by SFPs — yet we still see a major opening in the U.S., where ZYN shipments rose 37% even with first-half supply limitations, a notable price premium, and gaps in the competitive portfolio. Our Aspeya wellness unit likewise posted strong organic net revenue growth. Combustibles turned in solid top and bottom-line results, despite a more normalized decline in industry volumes and supply chain difficulties in Turkey. We got there via robust pricing, a resilient portfolio, and disciplined execution, with Marlboro notching a record-high share. Running this business responsibly lets us invest aggressively in better alternatives and keep our smoke-free momentum going. Taken together, all this let us achieve 15% adjusted diluted EPS growth in dollar terms — the best since 2011, if you set aside 2021, the pandemic recovery year. That equates to currency-neutral growth of 14%, far ahead of what we'd expected when the year began and the second consecutive year of mid-teens improvement. In fact, we've now met our three-year CAGR objectives for organic OI and currency-neutral EPS in just two years. With another robust showing anticipated in 2026, notwithstanding certain transitory headwinds, we are today extending these growth objectives for the coming three years, which further confirms our best-in-class growth profile among consumer packaged goods companies. What's key here is that this comes with robust cash flow that keeps growing, and by the close of 2026, assuming exchange rates stay where they are, we're aiming for a leverage ratio near 2x. Since our dividend payout is now right around the roughly 75% of adjusted diluted EPS that we're targeting, there's room to deliver solid returns to shareholders. Before handing things to Emmanuel, I want to call out a number of significant milestones we hit as we began the second decade of our smoke-free journey. In 2025, total net revenues came in above $40 billion, and 41.5% of that — nearly $17 billion — came from our smoke-free business. What's even more striking is the gross profit contribution from smoke-free, which has basically doubled over five years, now at 43% of total PMI. Our adjusted operating margin likewise climbed back above 40% this year, reflecting how our transformation keeps growing profitably. Smoke-free now accounts for a growing share of our business, with 27 markets passing the 50% net revenue threshold — among them South Korea, Poland, Italy, Romania and, naturally, the U.S., which also ranks among eight markets above 75%. During the final quarter of 2025, the Europe region moved past 50% as well, meaning three of our four regional segments are now majority smoke-free. We kept expanding our global smoke-free footprint, now at 106 markets, and 52 of those already run a multi-category strategy — a crucial catalyst for consumer uptake and growth over the long term. As adult nicotine consumers look for improved alternatives to smoking, we remain at the forefront of the wider industry transformation. Japan stands out as a prime illustration, where the heat-not-burn category went past the 50% total industry threshold in December, powered by IQOS's unabated strength. Throughout our 106 smoke-free markets, double-digit adjusted IMS volume growth keeps us ahead of the industry, showing the combined power of our leading brands. Proud as we are of our progress to date, we stay firmly focused on what's ahead, with an exciting pipeline of initiatives and innovations spanning the next three years. Underpinning this are growing digitalization and our new organizational model. With that, I'll pass it to Emmanuel to go deeper into our results and outlook, and I'll return at the close of this presentation.
Emmanuel Babeau
executiveThanks, Jacek. Let me begin by walking through the year's headline financials, which were truly impressive. Our organic top-line and operating income growth both finished inside the forecast ranges we established at the outset of 2025, and currency-neutral adjusted diluted EPS growth exceeded those expectations by 1.7 points. Organic top-line growth of +6.5%, or +7.9% once the technical Indonesia impact is excluded, came from positive shipment volume, a robust smoke-free category mix, and pricing — putting us at the upper end of our +6% to +8% mid-term CAGR targets. We also recorded yet another year of double-digit organic operating income growth, at +10.6%, which sits above our mid-term target range and reflects +140 basis points of organic margin expansion; in dollar terms, adjusted operating income climbed +11.8% to $16.4 billion. Currency-neutral adjusted diluted EPS growth was excellent at +14.2%, ahead of our expectations; the drivers were strong underlying business performance, especially in international multi-category and in combustible, together with a more favorable effective tax rate and lower net financing cost; measured in dollars, adjusted diluted EPS reached $7.54, at the high end of our last guidance range, even though the currency tailwind came in below expectations at $0.04 owing to non-recurring transactional losses in Q4, largely tied to the Russian ruble and the Swiss franc. Robust cash generation enabled us to deliver operating cash flow of $12.2 billion, matching the record set in 2024. Turning now to Q4 specifically, growth rates came in below the full-year level, partly because of the shipment and phasing factors we laid out last quarter, yet underlying performance surpassed our expectation. That allowed us to deliver adjusted diluted earnings per share growth of almost plus 10%, to $1.70, or plus 9% excluding a $0.01 currency tailwind. I'll now walk through our 2025 performance in more detail, beginning with volumes. As Jacek noted, we achieved our fifth consecutive year of positive volumes, with total shipment growth of +1.4%. The drivers were the continued dynamism of our smoke-free business, which has generated more than 100 billion incremental units over the past five years, combined with a very resilient cigarette performance; in 2025, smoke-free shipments rose +12.8%, or +20 billion units, to 179 billion, more than offsetting the 1.5% decline in cigarette shipments. Every smoke-free category grew strongly, with IQOS HTU shipment growth of +11% to 155 billion units, VEEV +102% to 3.3 billion equivalent units, and overall smoke-free product +18.5% to 20.7 billion units. Notably, that includes +37% growth from U.S. ZYN to 11.9 billion pouches, which accounts for close to 7% of total smoke-free product volumes. As expected, adjusted IMS growth for IQOS HTU accelerated in Q4 to +12%, while shipment volumes were impacted by the destocking last quarter and grew by +7.5%. Despite this impact, total Q4 smoke-free product volumes increased by a healthy +8.5%. Cigarette volumes for the full year came in down 1.5%, a touch ahead of the roughly 2% decrease we had anticipated, and our category share results during the back half held up well across a number of markets, Egypt and India among them. For the whole global cigarette business excluding China, volumes are estimated to have declined by approximately 1.1%. That number continues to reflect a two-track pattern: where smoke-free options are available, sales dropped by about 3%, whereas markets that prohibit those products or see only tiny uptake were essentially flat. In terms of how our 2025 top line came together, each key building block performed very much in line with its five-year average, demonstrating that these growth drivers are durable. The first pillar of our growth is volume expansion. The second pillar, price, contributed 4.1 points. The 2025 result was powered by a 7.6% combustibles price increase along with low single-digit pricing for IQOS, though U.S. ZYN promotions returning to normal in the second half partly offset that. Smoke-free mix is pillar three, adding 3.5 points in 2025. Geographic mix within combustibles and other items subtracted 1.1 points, while currency and scope effects contributed a gain of 0.8 points, and there was a $0.01 currency tailwind. Now let's walk through the full-year results by category. Both smoke-free and combustible lifted net revenue and gross profit, and gross margin rose organically 220 basis points to above 67%. Organic smoke-free net revenue increased 14.1%, with gross profit up 18.7%. As a result, adjusted gross margin advanced 270 basis points to 69.5%, widening the gap versus combustible to 4 points for the year. Once again, IQOS accounted for most of this, combining global top-line momentum with larger scale and improved cost efficiency. VEEV's profitability improvements also contributed, and while U.S. ZYN's commercial activity normalizing in the second half pressured year-over-year comparisons, its gross margins remained best-in-class — above our IQOS business average, even in Q4. As we noted three months ago, we view this as a durable favorable mix factor. Combustible delivered a solid 2025, with low single-digit top-line growth and low to mid-single-digit gross profit growth — a strong signal of what this unit ought to deliver going forward. Strong pricing more than offset volume decline and unfavorable mix, and disciplined cost control pushed gross margin up 160 basis points to 65.5%. Moving to operating margins, organic expansion for the full year reached 140 basis points, or 160 basis points in dollar terms, lifting adjusted operating income margin to 40.4%; we achieved that in a year of substantial commercial, marketing, and brand-building investment behind our smoke-free portfolio, spanning international multi-category launches and U.S. ZYN; we're also continuing to invest in expanding our U.S. capabilities so we can capture the significant growth opportunities ahead. This was made possible by a relentless focus on cost of goods sold and back-office efficiency, which enabled meaningful margin gains even as we keep funding growth. Starting back in 2024, we've delivered around $1.5 billion in gross cost savings, which keeps us firmly on track toward the $2 billion goal we've set for the 2024 through 2026 period. Now let's turn our focus to the smoke-free side of the business, where each category carries real weight. Our global reach continues to grow — PMI smoke-free products are available in 106 markets today. That includes the recent ZYN launch in Argentina as well as the IQOS debut in Taiwan. The number of markets offering all three categories climbed to 26, compared with 9 markets just two years ago. Yet again, our growth is outpacing the broader smoke-free market. Looking at the categories where we compete within those same 106 markets, our estimated in-market sales volume growth for the year exceeded +12%, whereas the industry grew only slightly above 9%. On that same basis, we estimate our volume share of smoke-free products at about 60%, and our share of category growth in 2025 is more than 70%. With our roster of leading premium brands, our smoke-free value share sits comfortably above 60%. As both our portfolio and geographic reach expanded, estimated legal-age consumers of our smoke-free products reached 43.5 million as of December 31st — about 10 million additional users compared with two years ago, with increases seen broadly across categories. IQOS adjusted IMS growth accelerated to an impressive +12% in the fourth quarter, reflecting strong momentum globally and a presence now extending to 79 markets. We also saw a $0.01 currency tailwind.
Emmanuel Babeau
executiveEach geography contributed, and we saw standout performance across major metros such as Mexico City, Manila, Riyadh, Rome, London, Madrid, and Munich. You'll find further detail on key cities and the European share in the appendix to these slides. That supported full-year growth of +10.5%, which put us within our target range. Annual adjusted IMS increased again, up by about 15 billion units, despite the continuing EU characterizing flavor ban working against us and intensifying competition. Our global heat-not-burn share remains exceptionally strong at roughly 76%. Brand engagement programs and continuing innovation across devices and consumables underpin this, including the ongoing launch of IQOS ILUMA i, which has now reached 55 markets altogether. Importantly, IQOS profitability continued to rise, driven by pricing, scale, and productivity improvements in consumable and device costs; a substantial increase in product contribution over time reflects this. Turning to nicotine pouches, ZYN remains the global number one, with a 2025 PMI category share of approximately 40% in pouch terms. The U.S. represents about two-thirds of the category today, while international markets, still relatively small, are growing rapidly; we achieved strong progress this year, expanding ZYN's footprint by +19 markets to 56 and delivering +36% shipment growth to 13.6 billion pouches, or 880 million cans — equivalent to 213 million cans — reaching our 2026 target a year early. U.S. shipments rose +37%, while international volume grew +31%, or +112% excluding the more mature Nordic market, where Q4 results faced a tough shipment comparison; our focus is on the category's future growth, broadening our portfolio to serve legal-age smokers seeking to switch. That includes new strengths and flavor variants, such as ZYN X-Low, 1.5 mg, which launched successfully across about two-thirds of ZYN markets, driving a notable improvement in first-experience acceptance among adult nicotine consumers. Though we remain at an early stage in developing this category, which represents only a low single-digit share of total nicotine in most markets, it is very encouraging that ZYN's share of international pouches, excluding the Nordics, increased by approximately +60% in 2025 to reach 16%, following the launches and relaunches of the past 1 to 2 years. In e-vapor, VEEV is the fastest-growing international vape brand among any major player in closed pods. The pod segment is expanding quickly as disposables decline, and VEEV is gaining considerable volume share in a fragmented landscape, drawing mainly from legal-age users of other vaping products and adult smokers. As mentioned earlier, shipments doubled over the year alongside a meaningful profitability gain. VEEV now operates in 47 markets and performed notably well in Italy, Romania, Greece, the U.K., Germany, and Indonesia. Now looking at the smoke-free portfolio by geography, starting with Europe, where as a segment, smoke-free products now account for over 50% of regional net revenue. Okay, when you put IQOS, ZYN, and VEEV together, our total volume rose a strong 13% for the year, and we see plenty of room for further growth from here, because SFP penetration as a whole remains low compared with what we observe in Japan or the U.S. IQOS delivered another strong quarter, and adjusted IMS growth in fact accelerated, hitting +10.3%. Italy stood out, where we handled the impact of the flavor ban effectively, supported by innovation introduced recently. Momentum strengthened as 2025 went on, keeping us on course for double-digit in-market sales growth for the full year, while quarterly market share went above 20% for the first time ever. Several other markets deserve mention for strong double-digit increases: Bulgaria, Germany, Greece, Spain, and Romania. On ZYN pouches, shipment volumes rose 9% for the year, and while the Nordics represent almost 60% of regional volume, shipments elsewhere more than doubled, with good momentum in the UK, Poland, Italy, and Austria. As we said earlier, VEEV continues to perform very well, with shipments up 110%. Now to Japan, where December delivered a significant milestone: heat-not-burn surpassed 50% of total industry offtake volumes, driven by IQOS's continued strength. Reaching 50% was not a smooth path, and after 2023 and 2024 brought two years of very strong expansion, category growth moderated in 2025. IQOS HTU adjusted in-market sales growth followed that same pattern, reaching a healthy +7% for 2025, which remains very strong in absolute terms. In Q4, both the Japanese nicotine industry and the heat-not-burn category grew somewhat below the full-year trend, partly because inflation is pressuring consumer spending. Still, IQOS HTU adjusted IMS increased 5.8%, and Q4 adjusted share rose 2 points from a year earlier, finishing at 32.6%. Competition clearly intensified this year, yet IQOS category share remained broadly unchanged, with most of the movement occurring among other players. We're encouraged by early signs that greater category activity is attracting more interest from more traditional adult smokers — a positive signal for category growth. Going forward, the heat-not-burn excise tax increases arriving in April and October mean 2026 will be an unusual year. As we discussed at the Morgan Stanley conference in December, the extent of pass-through becomes a headwind for the category — about JPY 50 to JPY 100 per pack, equivalent to 2%-10%-20% of current retail prices, with the heaviest impact on products at lower price points. We announced recently that we've filed an application to raise our prices in April. We expect those increases to weigh on category growth and volume in 2026, even though heat-not-burn consumers have historically shown greater price resilience than cigarette smokers. Shipment volatility in 2026 is also possible, driven by in-market sales trends surrounding the April and October excise increases. What matters most is that we don't see the fundamental category growth pattern shifting, and over the coming years we're aiming for considerable additional expansion from IQOS in Japan; we're likewise happy to share that ZYN's pilot launch in Tokyo went well. If you look past America, Japan, and Europe, all three of our smoke-free segments are delivering strong, broad-based momentum, with full-year shipments up 17%. That takes in IQOS's notable Q4 entry into Taiwan, where it ended the year at about 4% offtake share, along with rapid progress in markets such as South Korea, Malaysia, and the Philippines. In Pakistan and Mexico, ZYN demonstrated particularly strong pull. Turning to e-vapor, VEEV posted excellent numbers, above all in Asia. All three brands get extra support from our global travel retail business, which continues to deliver outstanding multi-category performance and serves as a powerful showcase for our portfolio. Moving now to America, which represented about 7% of our net revenues worldwide and around 8% of adjusted operating income in 2025. Nicotine pouches remain the fastest-growing category in the U.S., accounting for a high single-digit share of total nicotine industry volume. Despite supply constraints, commercial normalization, and portfolio gaps, ZYN held onto category leadership all through 2025 on the strength of its premium proposition, capturing about 50% of category growth, 61.5% can volume share, and value share exceeding 67%. ZYN offtake volume also rose substantially, gaining 25% across the year, per Nielsen estimates. Shipments were up 37%, equivalent to 230 million cans, to reach 794 million. That gap between shipments and offtake reflects a net channel inventory rebuild, and we estimate the underlying 2025 shipment base, in line with consumer offtake, was roughly 740 to 750 million cans, including 213 million cans.
Emmanuel Babeau
executiveThe bulk of this landed in 2025's first quarter, and our estimate for the underlying quarterly shipment base across 2025 comes to roughly 160 million cans during Q1, 180 million cans during Q2, 205 million during Q3, plus 200 million during Q4. As it turned out, Q4 brought destocking that fell below expectations — approximately 5 million cans — while we rolled out promotion, limited time offers, and in December announced a January list price increase of $0.10 per can. Turning to 2026, ZYN shipment volume should by and large track offtake growth off that underlying base, ahead of any additional channel inventory movement. We believe there's about 25 million cans of extra inventory still sitting in the downstream supply chain, and we expect that to work itself out in the normal course, most likely sometime in the first quarter. When it comes to how much ZYN offtake will rise in 2026, three main factors we're putting investment behind will determine that. Looking at the mid to long term, the single most important factor is ZYN's brand equity, and that's because we're responsibly ramping up our marketing, improving how visible we are at the point of sale, and building a stronger bond with consumers of legal age. As for reaching every segment of the U.S. With nicotine pouches, we'll have to steer through a regulatory landscape that keeps shifting and stays unpredictable. To serve a wide range of what consumers want, we've built out an innovation and are getting set to bring it to market. Several ZYN applications are still awaiting FDA review, and ZYN Ultra is one of them — it's part of the agency's pilot program. ZYN Ultra delivers stronger nicotine levels, plus a lineup of adult-focused flavors that's expected. We're taking the necessary steps so ZYN Ultra can launch at the earliest opportunity, once the FDA acts. In addition, we feel that IQOS ILUMA's solid application and proven history of switching smokers toward reduced-risk options justify prompt FDA movement. On top of that, we continue to fine-tune the premium pricing stance for ZYN. Despite heavy discounting across the whole category, ZYN remains the top premium brand by a wide gap, which fits perfectly with our plan for growth that lasts over the long term. We have a full commercial push lined up for 2026, and keep in mind that in the first six months of 2025, commercial efforts—promotions included—were unusually light. As I said earlier, we still anticipate ZYN will turn in the best gross margin at PMI, higher than the IQOS average. The brand's sizable room to grow in the years ahead has us quite enthusiastic, and it more than warrants the investment I just described. A good example of how we're stepping up brand building is the global partnership we announced not long ago linking ZYN with Ferrari. That deal honors the deep roots we've had in Formula 1 over the years, and now smoke-free offerings sit front and center. Since Formula 1 draws an audience that is overwhelmingly adults, it gives us a very powerful stage on which to connect with consumers in a responsible way and to strengthen ZYN's premium equity. Last, turning to combustible, which posted yet another strong year for pricing at +7.6%, with +6.8% coming in Q4, along with really solid gross profit growth. For the entire year, our cigarette share went down 0.2 points, landing at 25.3%, driven largely by Turkey, while everywhere else it held steady, and that includes an all-time peak for Marlboro, both across the full year and in Q4, when its share hit 11% of the international category outside China. Looking ahead to 2026, we're projecting a combustible pricing variance of roughly +6%, which reflects ongoing dynamic performance. So with that, I'll turn things back over to Jacek.
Jacek Olczak
executiveThanks, Emmanuel. That takes me into what we're expecting for 2026, and we anticipate yet another year of strong, profitable expansion even with a number of temporary headwinds in play. Let's begin with volumes. Across each of our three categories, we anticipate sustained solid underlying momentum in the smoke-free segment. After accounting for the Japan excise tax pressures and the U.S. ZYN inventory comparisons we described earlier, we project both shipments and adjusted IMS volumes to rise at a high single digit rate. Turning to combustibles, we see cigarettes falling roughly 3%, driven by softer industry volumes in India and Mexico after the recent excise tax hikes, while our continued rebound in Turkey is expected to weigh on comparisons during the first half. On the whole, that leaves us with a broadly flat view on total shipment growth, barring the customary swings in shipment timing and trade inventory shifts, versus an expected total industry contraction of roughly 2% for cigarettes and HTUs. We anticipate yet another robust year for pricing overall, led by combustibles, despite the effect of U.S. first-half comparisons, along with continued favorable smoke-free mix. Pulling everything together, for 2026 we're looking at organic net revenue growth in the 5%-7% range. Those same factors, together with operating leverage and ongoing cost efficiencies, ought to produce further meaningful margin improvement, and we're forecasting organic operating income growth of 7%-9%. That number accounts for the continued significant investment we're making in our smoke-free portfolio. We expect currency-neutral adjusted diluted EPS growth of 7.5%-9.5%, with net finance costs assumed to remain about level and an effective corporate tax rate close to 2025's, at approximately 21.5%. Adding an anticipated $0.28 currency benefit based on current exchange rates brings that to 11.3%-13.3% growth, or a range of $8.39-$8.54 — which would mark one more year of double-digit EPS growth when measured in dollars. We're expecting a big acceleration in the cash we generate from operations, getting to about $13.5 billion using current exchange rates, though year-end working capital requirements will play a role. That strong cash flow ought to support more significant debt reduction during 2026, which I'll discuss in more detail in a moment. If you break it down by quarter, the first quarter looks like the softest stretch of the year, reflecting difficult prior-year comparisons and how our investment spending is timed. Combustible volumes in Q1 should fall by up to 5%, as we're going up against a prior-year quarter that saw volume growth and absorbing what we expect to be the heaviest hit from the Turkey, India, and Mexico factors I mentioned for the full year. U.S. dynamics will similarly weigh on smoke-free product shipments. The ZYN shipment trends Emmanuel talked about, plus that difficult HTU comparison, played a role here, since the prior year had only limited ZYN commercial activity, which dragged down the net revenue per can figure. Because phasing put more global investment behind smoke-free in this quarter, we expect first-quarter organic net revenue and operating income to come in about even with last year. For adjusted diluted EPS, we're projecting high single-digit growth, landing between $1.80 and $1.85, and that includes a $0.14 benefit from current exchange rates, aided by an easier comparison against last year's transactional currency effects. As I mentioned earlier, we reached our three-year CAGR targets for operating income and EPS in just two years. When you combine what we're projecting for 2026 with the strong performance we delivered in 2024 and 2025, our expectation is that we will equal or exceed each CAGR objective for 2024 through 2026 that we introduced back at our 2023 Investors' Day. This is especially true when it comes to growth in operating income and EPS, despite the fact that our model had assumed a more advantageous corporate tax rate. Beyond that, the adjusted EPS CAGR we project, measured in dollar terms, represents a robust double-digit result. That brings me to the 2026 to 2028 outlook, in which we are restating our medium-term growth objectives for the next three years. We continue to target positive total shipment volumes, since gains in smoke-free products outweigh the drop in cigarette volume by more than enough. Even though our 2026 guidance ranges are a touch lower due to the particular reasons we laid out, looking at the full three years ending in 2028, our goals remain: organic net revenues growing 6%-8% compounded annually, organic operating income up 8%-10% compounded annually as margins widen, and adjusted diluted EPS rising 9%-11% compounded annually at constant currency. These updated objectives show how confident we are in keeping up a robust rate of growth on both the top and bottom lines over the long haul. They also confirm once more that we hold a best-in-class growth profile among large-cap consumer packaged goods companies. For smoke-free products, we aim for shipment growth and Adjusted IMS volume growth in the high single-digit to low teens range. Expanding smoke-free products internationally remains our primary growth engine, driven largely by our multi-category approach, and the sizable U.S. opportunity gives it even more momentum. As the period unfolds, we anticipate added support from market entries that are new as well as a robust pipeline of innovation. Bringing IQOS ILUMA to the U.S. sits among those objectives, and that covers the first round of commercial spending, with the exact pace depending on when the launch occurs. At the same time, our combustible business's durability serves as an essential foundation, supplying the infrastructure, the financial resources, and the ties to consumers needed to speed up smoke-free expansion. We're eager to tell you more about this at CAGNY on February 18th. Our business continues to throw off a lot of cash. That comes from how strong our brands are, and it's helped along by tight control over costs and cash. Because of this, we have the financial room to put significant money behind our smoke-free business, keep shareholder returns at a superior level, and make our balance sheet as efficient as possible. Looking ahead across the coming three years, we're aiming for total operating cash flow of roughly $45 billion, using exchange rates as they stand today. On capital expenditures, we expect an average of about $1.3-$1.5 billion each year, and there's a chance those amounts could come in lower after 2026. Once again, the biggest portion of that investment goes toward smoke-free products. Beyond strong business performance, we're dedicated to providing superior value to our shareholders. Since we've basically hit our goal of paying out roughly 75% of adjusted diluted EPS as dividends, we're now able to grow the dividend at a rate that's nearer to how earnings are growing — the 8.9% bump we announced in September of last year is proof of that. With strong cash flow and a lot of growth in our technology segment, we're well positioned to bring down what we owe. At the end of 2025, our adjusted leverage ratio came in at 2.5x, reflecting real progress despite the fact that unfavorable currency movements late in the year held back our net debt. Looking ahead to 2026, we anticipate additional gains, aiming for approximately 2x by the time the year ends based on exchange rates in effect at that time, which would give us greater room for allocating capital; to sum up, our results for the entire year highlight how powerful and dynamic our worldwide smoke-free operation has become, underpinned by spending on our premium labels and the ongoing durability of combustible products. Even with a challenging business landscape defined by economic instability, geopolitical strife, and shifting regulatory frameworks, we kept achieving notable strides toward our goal of a future without smoke. Having produced steady top-tier growth, we are putting money back into our flagship labels, new products, and the essential competencies that underpin sustained results. This empowers us to create considerable worth for our stockholders, among which is the biggest dividend raise seen in more than 10 years; we face 2026 and the years after with assurance. I appreciate that, Emmanuel, and at this point I am glad to take your questions.
Matt Smith
analystHello, and thanks to both Jacek and Emmanuel for taking the question I have.
Emmanuel Babeau
executiveMorning there, Matt.
Matt Smith
analystLet's begin with those new medium-term targets you gave us today. Could you say more about why smoke-free volume growth picks up again versus what the 2026 guidance shows? You also mentioned America as an additional market in the outlook. What about other markets that remain closed at present, and the chance to bring platforms into IQOS markets that already exist? Thank you.
Emmanuel Babeau
executiveRight, so at this point the faster pace after 2026 comes mostly, in our view, from everything tied to the tax adjustments or price moves driven by excise in Japan. As you might remember, Japan has a multi-step excise tax change for tobacco nicotine products. It begins with the asymmetry of heated tobacco products seeing taxes rise first, and then cigarette prices going up starting in 2027. So I think for now there will be certain headwinds, or perhaps certain headwinds, for category growth and clearly for IQOS growth in 2026, yet once we get into 2027 and later, with greater symmetry in fiscal policy and how cigarettes and heat-not-burn are treated — I mean IQOS or the category — growth should come back or restart; that's one element. And the second element, clearly, is that, as we pointed out in our remarks, there is a very competitive situation in America, and even though America in total smoke-free volumes perhaps carries limited weight, when it comes to growth, chances and expansion it matters a great deal to us. There are certain asymmetries in the portfolio compared with what is presumably the most dynamic portion of the overall market, and we think that with the pending authorization from FDA, once we get moving, hopefully during 2026, but certainly 2027, and so on, we will align the portfolio with what consumer market expectations are. Now, clearly, the other elements we referenced sit more on the combustible side — I mean, not with smoke-free products. I mean, we cited India, Mexico, perhaps a few other smaller locations that have rather outsized, I would describe them, excise increases, which clearly will produce rather outsized increases beyond the usual price moves. So I think once we will — we don't expect this to be the kind of recurring events in 2027, 2028, so we can return and restart strong top-bottom-line growth in the later years. I think I've just covered the main drivers. There is clearly the innovation element, but you will ask me what the innovation actually is, and for competitive reasons I cannot reveal it, yet this will be the primary drivers arriving or beginning in 2026. The excise in Japan, excise in a few other locations, and a ZYN portfolio asymmetry, and moving that toward symmetry.
Matt Smith
analystThat's quite straightforward. I appreciate it. I'm looking forward to our meeting at the CAGNY conference, and I will share that with the team.
Emmanuel Babeau
executiveLikewise, Matt. Thanks.
Eric Serotta
analystGreat. Thanks so much. The guide for 2026.
Jacek Olczak
executiveEric, good morning.
Eric Serotta
analystAh, good morning. Regarding your 2026 outlook for smoke-free volumes, which sit somewhere between high single digits and the low teens, what's your big-picture thinking? I realize you aren't providing formal guidance, but how do you view things for IQOS, HTU shipments, and IMS? Clearly, certain headwinds exist that you flagged, such as the excise situation in Japan. Then, on the competitive side in Japan, my understanding is that things began intensifying around Q2 of last year, when some rival products launched. How has this been developing sequentially, especially as we now enter the period in which competitors have submitted their price increase filings to the Finance Ministry?
Emmanuel Babeau
executiveOkay, let me begin with the latter portion of that second question. There's no doubt that in both this year and the previous one, competitive intensity picked up in Japan. When I look at how firmly IQOS retains its share there and keeps expanding, things appear to be going quite well. Consider that we've spent 10 years building the IQOS brand in Japan, through many smaller moves as well as major innovations, IQOS ILUMA among them. So my sense is that IQOS is heading into this stretch — which is somewhat demanding on the price and excise side — from a fairly solid position. That said, there are entirely fair questions about how we view IQOS in Japan, yet we prefer not to provide highly specific volume figures or other projections for any single geography, since, as you can understand, competition exists, and we don't wish to say too much and expose our intentions regarding pricing, share targets, and volume targets. Still, when we release guidance for total smoke-free product volume movement in the coming year, all such elements are incorporated, so to speak. And perhaps, Eric, regarding your first question, on the worldwide IQOS picture within that high single-digit expansion for our SFP volume in 2026, we're extremely happy with how IQOS is growing. We closed out 2025 on a very strong note, with adjusted in-market sales growth above 12%. True, Japan has decelerated somewhat, as we noted, yet several markets sped up again. Italy is among them. Across Europe, a number of markets are, I'd say, gaining momentum, such as Germany and Spain. You also have places like Romania and Bulgaria that add a very welcome complement to the growth. So the overall picture for IQOS looks great, and naturally we carry on, or rather we anticipate carrying on, in 2026; plus you have all those additional markets in emerging economies performing very well. We have Indonesia, the Philippines, the Gulf, Mexico. There are, in short, many markets where IQOS is picking up speed. And finally, we're delighted about the Taiwan launch. Just 4% within a few short weeks — that's a real accomplishment, and we're enthusiastic about what lies ahead. So taken together, that paints a favorable picture for IQOS carrying on with very solid growth in 2026.
Eric Serotta
analystOkay, one thing I want to make sure we're clear on, specifically regarding the guidance for the midterm, meaning 2026 through 2028. If I'm mistaken, please correct me, but my understanding is that nothing for ILUMA in the U.S. is baked into 2026, while something is indeed factored in for the 2027 and 2028 period. Is that accurate, or please tell me if I've got that wrong?
Jacek Olczak
executiveYes, it's broadly fair. Well, as you know.
Eric Serotta
analystEric, I’ll relay that.
Jacek Olczak
executiveNo, no, no, no—joking aside, apologies. Seriously speaking, across the past 2 years we’ve had quite a few conversations about when this FDA authorization, which has been delayed far too long, might be estimated or expected to arrive. Still, in some way we built assumptions for IQOS coming into the U.S. market during a projected window, yet I don’t believe the algorithm we presented to you today leans heavily or materially on IQOS in the U.S. That said, IQOS is in there, both in terms of investment and some anticipated volume.
Eric Serotta
analystGot it. Thanks so much. I'll pass it on.
Jacek Olczak
executiveThanks, Eric. Appreciate it.
Bonnie Herzog
analystOkay. Thanks. Hello, everybody. Hi there. I'd like to dig deeper into Japan and what's happening with excise taxes. Like you said, we're aware — or we've observed — that you're seeking, or you did seek, a price hike on top of that tax. So I'm hoping you can share more about what elasticities you anticipate, since volumes, I'd imagine, will take a fairly negative hit. And then, I suppose, will the leverage from that additional pricing you're aiming for be sufficient to generate margin expansion and income growth in that region?
Jacek Olczak
executiveYeah, this is Jacek. Bonnie, hello. All right, consumers will begin feeling the impact of prices. We'll begin to observe those prices starting April 1, correct? So that's still somewhat ahead of us. Clearly, there will be certain IMS shipment kinds of distortions. Consumers might purchase some ahead of time, or perhaps they won't. I mean, all such things will more or less wash out over the course of the year. Now, heated tobacco products face two stages of excise increases during 2026, one that, again, will reach consumers on April 1 and a second one in October, all right? The magnitude, or the scale, of that excise hike might not right away justify — and I don't wish to discuss the pricing strategy and so on at this point — might not right away justify; it hinges on which strategies are in play regarding margin expansion. But I do trust that our method of passing along prices and continually striving toward margin expansion — I think across a somewhat longer stretch of time, we'll reach where we intended to reach. However, I can't say anything further, Bonnie, for reasons that are obvious.
Bonnie Herzog
analystI had a feeling. Okay. That was useful nonetheless. Thank you. And next, I wanted to ask something big-picture about the guidance for this year. Could you lay out for us, or at least touch on, the main growth drivers that will let you hit — and maybe exceed — your top- and bottom-line guidance, given that you're going up against a number of strong growth years? Given the momentum, that's been a central question. So it would help if you could sketch out for us what the main drivers behind this are. And along those lines, I wanted to confirm how much of a bump, if any, your guidance bakes in for planned investment spending this year compared with last. Again, I'm asking with everything you intend to roll out in mind, which of course hinges on the FDA. Thanks.
Jacek Olczak
executiveLook, I mean, clearly, we are making certain assumptions regarding the FDA. Okay, let me take a different approach to answering. If we focus specifically on ZYN and the ZYN Ultra application still pending, which sits very much in the higher nicotine strength, obviously the moist version, some flavors, and so on, we are ready to launch the product basically as we speak. So everything now hinges on how fast an answer comes back from FDA. And if I may, I'll avoid any fortune-telling about the exact timing from FDA. I mean, my past record at forecasting FDA wasn't great, so I have to let go of a bit more of that. But I believe it will happen, okay? Summer this year, I think the plan is well balanced. Obviously, we will be — I mean, sorry — ZYN is expanding in the U.S., but it isn't expanding at the level we expect if you compare category growth with ZYN growth, at least as of late, and so on. I mean, that will need to be addressed. IQOS, as I mentioned, is to some extent baked into the plans, and the way we constructed this algorithm gives a solid balance among timing, volume expectations, and investment. Now, we have to keep in mind that when we discuss ZYN and VEEV, for instance, internationally, I mean, these two product categories benefit enormously from the infrastructure we've built over time around IQOS. And I believe the longer we wait, including in the U.S., we might wind up with something similar but reversed; it's ZYN, and its infrastructure, back-office capabilities, and so on, that will eventually start being shared for IQOS. So I recall you always asked those questions about how much we'll put behind an IQOS, but it all hinges on what other investments we've been making up to this point, and so forth. Clearly, there will be some variable investment. You have to create awareness and things like that, but that isn't especially heavy, perhaps organized, enduring investments that are already in place since we keep putting money behind ZYN. Bonnie, just to add perhaps, there is no break in 2026 compared with how the past years have trended. So the core drivers stay precisely the same. You have a strong smoke-free portfolio that keeps being dynamic. Yes, you have this situation in Japan, which is a one-off. You have the elevated comparison base in the U.S. that will matter when it comes to growth measured against what the actual underlying growth is. So that is something we factor in; but at the core, the dynamism is present. It arrives with a very good positive mix effect on margin, and that is working. On combustible, we have this resilient business model. Yes, in 2026, we anticipate a somewhat larger decline, which stems from, first of all, Turkey, where we still face an H1 of comparison, even though matters are steadily getting better. But chiefly two markets, India and Mexico, where you have enormous excise duty hikes that are set to occur. In India, you are talking about a 40%+ price rise for the consumer. So we will see a massive impact on those markets. So this affects volume; but despite that, we aim to have this resilient model where, with volume declining, we think we can grow revenue at low single-digit and gross profit at low to mid-single-digit; so as you can tell, the 2026 objective is not very distant from the core of the midterm growth algorithm. The fundamental stays precisely the same. We have a few special events that we will get past and offset, and that really is what drives the difference. But at the core, the powerful dynamic behind the business stays precisely the same.
Bonnie Herzog
analystAll right, that helps a lot. Thanks. I'll pass it along.
Faham Baig
analystGood morning, everybody. Thanks for letting me ask. I've got a few as well. Since we're nearing the fifth anniversary of the IQOS ILUMA introduction, I want to push you a bit on innovation, and we're curious about what comes after. In your view, which technical or functional aspects might fuel additional consumer switching, particularly in emerging markets? My other question is on ZYN once more. Over the last two months, we've seen an obvious absence of ZYN promotional activity in the U.S. Could you clarify if that's a deliberate shift as you await the launch of ZYN Ultra, that higher-strength option you mentioned, or does it reflect a different stance on how aggressively you want to pursue trial at this moment versus capturing the 50% category growth you've previously highlighted?
Jacek Olczak
executiveAll right. This is Jacek, I'll handle it. On the first one, it makes me happy and feels like an honor that someone covering PMI tracks PMI's innovation engine so closely. You've got it right. We're basically at a scheduled stage approaching five years for IQOS ILUMA. So your assumptions look pretty reasonable, though I won't answer the latter part of that question — namely what the innovation will be — for reasons I think everybody understands. Turning to promotions, I actually think it boils down to those two months. There's plainly a difference in the promotions and their intensity that the U.S. market executed in Q3 and Q4. Certain programs we decided not to run again, and those decisions were ours. Still, I wouldn't conclude anything from such a brief period regarding how intense promotional activity is. It's part of our plan. Again, I can't talk about this; but the way to view it, and I think we've been fairly transparent in our comments, is that three factors will shape long-term success for our pouch business in the U.S., and we're just repeating what we've consistently done internationally. The first is the brand, and you require a considerable level of backing through brand-building. Then, obviously, there's the portfolio element, which must align with at least current trends; we can debate separately which trends we think may persist longer, which could stick around; but the fact is ZYN does well in a dry segment of 3, 6 mg, yet it clearly lacks a higher nicotine strength, okay, maybe 9 specifically, maybe others, okay? So that's what we'll have to address, and there we must engage or work with FDA. Price is another component of this equation, obviously, and that's a premium the consumer will pay for ZYN in exchange for getting a trusted, lively, dynamic brand along with the right product. Part of this will be almost like going back to the textbook version of an old, perhaps neglected marketing mix, with roughly $1.3 billion to $1.5 billion per annum on average behind it. What we're after is the right price, the right product, the right place, the right promotions. Every one of these components is going to be rolled out as a group, and we'll do it carefully. Hopefully that at least gets you partway toward an answer on what you asked, and I'd add that on average this runs somewhere around $1.3 billion to $1.5 billion each year.
Faham Baig
analystNo, that's really useful. Since you didn't answer my first question, could I quickly fit in one more for Emmanuel?
Emmanuel Babeau
executiveOf course. Of course. Of course.
Faham Baig
analystEmmanuel, the guidance on currency for this year came in much stronger than what the Street had modeled. Could you walk us through the main reasons behind that, and also give us the hedge rates for the year on the major currencies? That would be a big help.
Emmanuel Babeau
executiveYeah. So I'd say the likely explanation is this: in 2025 we're set to gain from a fairly sizable negative transactional effect that won't recur, given where forex stands today, in 2026. When you look at that $0.27 guidance, two-thirds of it comes from translation, while roughly one-third comes from transaction. So my sense is that's likely the piece the Street is missing, naturally, since it's hard to capture. I won't give you the exact hedging figures, but yes, we still have some hedges in place that are giving us a bit of help, particularly on the yen, since the euro has been rising. So hedges on the euro aren't delivering much of a difference anymore; we do still get a rate that's modestly better than the spot rate showing on your screen. That's reining in the downside somewhat. To be clear, in 2025 the Japanese yen hurt us, and for 2026 we anticipate yet another hit from the Japanese yen.
Faham Baig
analystThank you. Appreciate it.
Emmanuel Babeau
executiveThank you.
Gerald Pascarelli
analystThanks, and I really appreciate you taking the question.
Emmanuel Babeau
executiveHello there, Gerald.
Gerald Pascarelli
analystHow's it going? I've only got one question. I'd really like to hear what you think. Last month, though, there was a report that New York is looking at a big increase in the excise tax on nicotine pouches. So I'd just love to hear your perspective, given the clear possibility that other states might put forward similar proposals, and then perhaps the effect you think this could have on the promotional environment or the competitive landscape. Thanks.
Emmanuel Babeau
executiveYeah. Of course, this proposal is on our radar. What I can say right now is that it works against the health benefit that nicotine or smokers get from these products. So I believe the legislator in that place is weighing everything. Look, U.S. states aren't all doing very well. Each is propelled by its own way of thinking, and actions taken by one state don't automatically carry over into what other states do. But we'll see how things develop. Once more, I'll say it, since for us it matters greatly that a shortsighted stance on excise for products that are far superior to cigarettes damages genuine public health goals. So I think it's simply a bad idea.
Gerald Pascarelli
analystThanks.
Damian McNeela
analystHello, and thanks.
Emmanuel Babeau
executiveHello there, Damian.
Damian McNeela
analystHello, and thanks. I've really got only a single item, and it concerns expenses. You mentioned that by the close of this year, the company remains on schedule to achieve $2 billion in cost savings. I'd like to know if you can put a figure on whether a comparable amount of savings ought to be anticipated under the medium-term guidance that concludes at the end of 2028, and how much room AI might have to speed those savings up, please.
Emmanuel Babeau
executiveRight, so this isn't included in the guidance we've given you today, though we definitely have the ambition of staying highly efficient with our cost base. Broadly, I won't provide the exact breakdown, yet approximately 60% falls under COGS, while the remainder sits in our back-office costs in particular, plus G&A; clearly, our aim is to create efficiency going forward that comes from AI. Once more, that subject becomes rather delicate when you begin stating how much to put in and what to anticipate from AI; even so, you should definitely count on AI serving as a driver of greater efficiency and of cost performance down the road, without question.
Damian McNeela
analystOkay. Thank you.
Emmanuel Babeau
executiveThank you.
Jacek Olczak
executiveOne final point from me — and honestly, nothing demonstrates better that we're operating in a world where you've got digital AI alongside people. Both of us are human. And it isn't a case of the AI making something up. When it comes to this year's guidance, I believe I misread a single figure. As for the currency impact heading into 2026, Emmanuel set the record straight on that figure — the one shown on your slide, the one included in the release, and the one Emmanuel cited as being correct. I'm sorry for any trouble this caused, but it proves better than anything that this was a conference happening live, not one run digitally. I'll see everyone at CAGNY. Many thanks.
Emmanuel Babeau
executiveSee you soon. Thank you for your time. Thank you.
James Bushnell
executiveWe appreciate you being here with us. If anything else comes up that you'd like to ask, feel free to reach out to our investor relations group, and we wish you a pleasant rest of your day.
Operator
operatorThat concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.